Study study type PathologyT1T0Patientssample sizesROB Results

mHCC - (neo)adjuvant (NA) metastatic/advanced hepatocellular cancer (mHCC) mHCC - (neo)adjuvant (NA)

versus nivolumab alone
nivolumab plus ipilimumab
NCI-2018-01106, 2022
  NCT03222076
RCThepatocell cancer (HCC)nivolumab plus ipilimumabnivolumabPatients With Resectable and Potentially Resectable14 / 13NA
inconclusive
    no statistically significant result
versus Standard of Care (SoC)
atezolizumab plus bevacizumab
IMbrave050, 2023
  NCT04102098
RCTmHCC - (neo)adjuvant (NA)atezolizumab plus bevacizumabactive surveillanceadult patients with high-risk surgically resected or ablated hepatocellular carcinoma334 / 334NA
conclusif
  • demonstrated 28 % decrease in RFS/DFS (PE)
sintilimab
Wang, 2024
  ChiCTR2000037655
RCThepatocell cancer (HCC), mHCC - (neo)adjuvant (NA)sintilimabSOc99 / 99NA
conclusif
  • demonstrated 47 % decrease in RFS/DFS (PE)
  • statistically significant 200.0-fold increase in AE (any grade)
  • statistically significant 26.2-fold increase in AE (grade 3-4)